STOCK TITAN

INSM Form 144 Discloses 10,000-Share Insider Sale by Melvin Sharoky

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Insmed, Inc. (INSM) Form 144 filing reports a proposed sale of common stock by an insider. The notice shows 10,000 shares to be sold through Merrill Lynch (Orlando address) with an aggregate market value of $1,294,600.00 and company common shares outstanding listed as 211,374,786. The securities were acquired via stock options on 05/13/2021 (5,865 shares) and 05/22/2024 (13,192 shares). A sale of 10,000 shares by Melvin Sharoky on 08/12/2025 is also reported with gross proceeds of $1,215,350.00. The filer certifies no undisclosed material adverse information. Specific filing date is not provided in the content.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine insider Rule 144 notice showing a small, non‑control sale; no new financial data.

The filing documents a proposed sale of 10,000 common shares by insider Melvin Sharoky under Rule 144, with the shares acquired via stock options in 2021 and 2024. The reported aggregate market value ($1.29M) and the prior sale on 08/12/2025 ($1.215M gross proceeds) are disclosed. Relative to outstanding shares (~211.4M), the amount is immaterial to capitalization and provides no operational or earnings information. This is a compliance disclosure rather than a material corporate development.

TL;DR: Disclosure meets Rule 144 mechanics; no indication of undisclosed material information.

The notice includes standard attestations about absence of undisclosed material adverse information and references potential Rule 10b5‑1 plans without specifying any plan adoption date. The filing identifies the insider, acquisition method (stock options), broker, and transaction amounts, fulfilling routine governance transparency requirements. No unusual transactions, departures, or governance actions are reported.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Insmed Inc

NASDAQ:INSM

INSM Rankings

INSM Latest News

INSM Latest SEC Filings

INSM Stock Data

37.70B
210.98M
0.65%
101.25%
5%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRIDGEWATER